Table 3.
Comparison of the prevalence of antimicrobial resistance between integron-positive and -negative Acinetobacter baumannii isolates.
| Antimicrobial | Integron-Positive A. baumannii Isolates (n = 296) | Integron-Negative A. baumannii Isolates (n = 129) | p Value |
|---|---|---|---|
| Ampicillin/sulbactam | 89.9% | 62.4% | <0.05 |
| Piperacillin/tazobactam | 92.7% | 65.2% | <0.05 |
| Ceftazidime | 98.5% | 75.4% | <0.05 |
| Ceftriaxone | 100% | 98% | <0.05 |
| Cefepime | 94.3% | 74.6% | <0.05 |
| Aztreonam | 99.6% | 93.1% | <0.05 |
| Imipenem | 86.6% | 65.8% | <0.05 |
| Meropenem | 89.9% | 57.6% | <0.05 |
| Amikacin | 87.8% | 42.7% | <0.05 |
| Gentamicin | 98.1% | 71.7% | <0.05 |
| Tobramycin | 93.3% | 62.7% | <0.05 |
| Ciprofloxacin | 98.7% | 77.7% | <0.05 |
| Levofloxacin | 86.2% | 55.4% | <0.05 |
| Sulfamethoxazole/trimenthoprim | 98.3% | 85.3% | <0.05 |
| Minocycline | 39.3% | 28.8% | 0.119 |